GLP-1 microdosers are chasing longevity

More than 10 percent of U.S. adults take GLP-1 drugs. But not all of them are taking full doses. Around one in seven users has “microdosed” injections, a recent survey by the health tracking app Evidation found. Some take tiny portions for practical reasons, such as cutting costs. Others have loftier ambitions: They hope to harness the drugs’ powerful effects to achieve better health and longer lives without losing a lot of weight or experiencing side effects such as GI issues and muscle loss.

Medications such as Ozempic and Wegovy mimic the body’s GLP-1 hormone, which helps regulate appetite, metabolism and blood sugar. That has made the drugs blockbuster treatments for type 2 diabetes and obesity. But to date, “there is no rigorous scientific data to support microdosing,” says bariatric medicine specialist Katy Williams of the University of Missouri Health Care in Jefferson City.

That hasn’t stopped some intrepid biohackers from trying it, though. Companies like AgelessRx, a longevity-focused telehealth clinic, explicitly sell GLP-1 microdoses for this purpose, advertising them as “a powerful new path to promoting long-term wellness.”

There is some research to suggest GLP-1s can promote healthy aging by improving overall health. The drugs have been found to reduce inflammation and oxidative stress, lower risks of major cardiovascular problems, lower cancer risk and more. Such findings have prompted scientists to study the drugs as potential treatments for illnesses as diverse as Alzheimer’s disease and arthritis. Some experts have even wondered whether the drugs’ systemic effects might slow cellular aging and prevent age-related chronic conditions, potentially making them the first true longevity drugs to hit the market.

But science hasn’t caught up to the hype. There’s scant published research on GLP-1 microdosing, although some teams are studying it. For instance, a low dose of the active ingredient in Ozempic and Wegovy might reduce alcohol cravings, researchers reported last year in JAMA Psychiatry. And AgelessRx is starting a clinical trial focused on how GLP-1 microdosing affects health and quality of life.

Some people aren’t waiting around for data. That includes many patients of Shamsah Amersi, an ob-gyn in Santa Monica, Calif. Amersi discusses microdosing with all patients entering perimenopause, she says, and about 60 percent of her patients over 40 use one. Amersi claims that the majority of microdosers under her care feel better and see improvements on lab tests measuring metabolic and overall health. “GLP-1 is one of the most transformative therapies in modern medicine,” she says, though she notes the drugs are not for everyone. Amersi thinks patients can benefit from microdosing now, even without data to prove its efficacy, if they work with a doctor to carefully monitor their response.

Other experts remain wary. There isn’t enough data to confirm that microdosing can help you live longer, says clinical pharmacist practitioner Anne Komé of the University of North Carolina Medical Center in Chapel Hill, who published a 2025 e-letter about microdosing GLP-1s in Diabetes Care. But it could help clinicians optimize therapy for patients who have trouble affording the drugs or who struggle with gastrointestinal issues or other side effects, she says. All medications come with potential risks and side effects. It’s not worth taking that chance when benefits are unproven, Williams says. She’d rather longevity seekers focus on diet, exercise and sleep.

Plus, people may be entering the Wild West if they buy GLP-1s online or from compounding pharmacies, she says. These outlets are not as strictly regulated as major drug manufacturers are. Customers can’t always be sure that what’s on the label matches what’s in the vial. “Save your money,” Williams says.